These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28947922)

  • 1. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver.
    García-Calzón S; Perfilyev A; Männistö V; de Mello VD; Nilsson E; Pihlajamäki J; Ling C
    Clin Epigenetics; 2017; 9():102. PubMed ID: 28947922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
    Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
    Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping of biguanide transporters in human fat cells and their impact on lipolysis.
    Arner P; Kulyté A; Batchelor K; Laurencikiene J; Livingston J; Rydén M
    Diabetes Obes Metab; 2018 Oct; 20(10):2416-2425. PubMed ID: 29862627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-layered epigenetic regulation of IRS2 expression in the liver of obese individuals with type 2 diabetes.
    Krause C; Geißler C; Tackenberg H; El Gammal AT; Wolter S; Spranger J; Mann O; Lehnert H; Kirchner H
    Diabetologia; 2020 Oct; 63(10):2182-2193. PubMed ID: 32710190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1.
    Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H
    Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.
    Ningrum VDA; Sadewa AH; Ikawati Z; Yuliwulandari R; Ikhsan MR; Fajriyah R
    PLoS One; 2022; 17(7):e0271410. PubMed ID: 35905099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease.
    Sundelin EIO; Gormsen LC; Heebøll S; Vendelbo MH; Jakobsen S; Munk OL; Feddersen S; Brøsen K; Hamilton-Dutoit SJ; Pedersen SB; Grønbaek H; Jessen N
    Br J Clin Pharmacol; 2019 Aug; 85(8):1761-1770. PubMed ID: 30973968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
    Zhou K; Donnelly LA; Kimber CH; Donnan PT; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Palmer CN; Pearson ER
    Diabetes; 2009 Jun; 58(6):1434-9. PubMed ID: 19336679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
    Yang J; Kalogerou M; Gallacher J; Sampson JR; Shen MH
    Eur J Cancer; 2013 Apr; 49(6):1479-90. PubMed ID: 23228442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus].
    Grzybowska M; Bober J; Olszewska M
    Postepy Hig Med Dosw (Online); 2011 May; 65():277-85. PubMed ID: 21677353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.
    Naem AAA; Al-Terehi MN; Ghafil FA; Ataya FS; Batiha GE; Alexiou A; Papadakis M; Welson NN; Hadi NR
    Endocrinol Diabetes Metab; 2024 Sep; 7(5):e486. PubMed ID: 39086121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans.
    Sundelin E; Gormsen LC; Jensen JB; Vendelbo MH; Jakobsen S; Munk OL; Christensen M; Brøsen K; Frøkiaer J; Jessen N
    Clin Pharmacol Ther; 2017 Nov; 102(5):841-848. PubMed ID: 28380657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
    Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
    Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
    Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
    Gene; 2022 May; 823():146382. PubMed ID: 35240257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by
    Dawed AY; Zhou K; van Leeuwen N; Mahajan A; Robertson N; Koivula R; Elders PJM; Rauh SP; Jones AG; Holl RW; Stingl JC; Franks PW; McCarthy MI; 't Hart LM; Pearson ER;
    Diabetes Care; 2019 Jun; 42(6):1027-1033. PubMed ID: 30885951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes.
    Abderrahmani A; Yengo L; Caiazzo R; Canouil M; Cauchi S; Raverdy V; Plaisance V; Pawlowski V; Lobbens S; Maillet J; Rolland L; Boutry R; Queniat G; Kwapich M; Tenenbaum M; Bricambert J; Saussenthaler S; Anthony E; Jha P; Derop J; Sand O; Rabearivelo I; Leloire A; Pigeyre M; Daujat-Chavanieu M; Gerbal-Chaloin S; Dayeh T; Lassailly G; Mathurin P; Staels B; Auwerx J; Schürmann A; Postic C; Schafmayer C; Hampe J; Bonnefond A; Pattou F; Froguel P
    Diabetes; 2018 Jul; 67(7):1310-1321. PubMed ID: 29728363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the rs3088442 G>A SLC22A3 Gene Polymorphism and the Role of microRNA 147 in Groups of Adult Pakistani Populations With Type 2 Diabetes in Response to Metformin.
    Moeez S; Riaz S; Masood N; Kanwal N; Arif MA; Niazi R; Khalid S
    Can J Diabetes; 2019 Mar; 43(2):128-135.e3. PubMed ID: 30297296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.